Lilly for the fourth time this year has announced refunds for overcharges on 340B-purchased drugs during 2019.

Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019

In Federal, Pharma Industry, RegulatoryJuly 6, 2022274 Views

For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.

The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website last week. Lilly said the 340B ceiling price adjustments for Q4 2019 are due to changes in Medicaid average manufacturer and best price “to account for lagged transactional data.”

For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Site Footer